Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals (LGND) is a biopharmaceutical company with a royalty-based business model, showing a single congressional trader making three purchases in 2026 totaling $3,003-$45,000, against zero lobbying spend, donations, or federal contracts.
BusinessWhat LGND does
Ligand Pharmaceuticals operates a diversified business model focused on developing and acquiring royalty-generating assets in the biopharmaceutical sector. It generates revenue through royalties on sales of partnered products, license fees, and material sales. The company's portfolio includes partnered programs with various pharmaceutical companies across multiple therapeutic areas.
12 months past · 3 months futureLGND activity timeline
Lifetime Government AwardsLGND federal contracts
LGND doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding LGND
Politicians Trading LGNDMembers of Congress with recent LGND positions
Congressional TradesWho in Congress is trading LGND
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
Bills Affecting LGNDLive legislation impacting this stock
Political ProfileWhere LGND sits in Washington
[object Object]
STRUCTURAL: Zero lobbying spend (get_political_influence.lobbying.total_income: 0), zero donations, zero federal contracts (get_government_precedent.federal_contracts_summary: null). EVIDENTIARY: Single congressional trader (bioguide_id C001123) made three purchases in 2026 totaling $3,003-$45,000; two corporate insider buys in May 2025 totaling $687,519 (CEO $583,629, CFO $103,890). Net: Evidentiary buys offset by lack of structural political engagement, resulting in neutral signal.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Potential legislative impact from multiple pharma-sector billsCongress"Recent bill_impacts array shows 8 bills with impact_ratios 0.0041-0.0054, each estimated revenue impact $15M-$19.5M"
Regulatory opportunities
- No specific regulatory opportunities flagged.
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for LGND — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades LGND
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord